1536 related articles for article (PubMed ID: 24309531)
1. Measurement of minimal residual disease before and after myeloablative hematopoietic cell transplantation for acute leukemia.
Appelbaum FR
Best Pract Res Clin Haematol; 2013 Sep; 26(3):279-84. PubMed ID: 24309531
[TBL] [Abstract][Full Text] [Related]
2. Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation.
Gilleece MH; Labopin M; Yakoub-Agha I; Volin L; Socié G; Ljungman P; Huynh A; Deconinck E; Wu D; Bourhis JH; Cahn JY; Polge E; Mohty M; Savani BN; Nagler A
Am J Hematol; 2018 Sep; 93(9):1142-1152. PubMed ID: 29981272
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of minimal residual disease analysis by flow cytometry in patients with acute myeloid leukemia before and after allogeneic hemopoietic stem cell transplantation.
Bastos-Oreiro M; Perez-Corral A; Martínez-Laperche C; Bento L; Pascual C; Kwon M; Balsalobre P; Muñoz C; Buces E; Serrano D; Gayoso J; Buño I; Anguita J; Diéz-Martín JL
Eur J Haematol; 2014 Sep; 93(3):239-46. PubMed ID: 24702162
[TBL] [Abstract][Full Text] [Related]
4. Pre- and post-transplant quantification of measurable ('minimal') residual disease via multiparameter flow cytometry in adult acute myeloid leukemia.
Zhou Y; Othus M; Araki D; Wood BL; Radich JP; Halpern AB; Mielcarek M; Estey EH; Appelbaum FR; Walter RB
Leukemia; 2016 Jul; 30(7):1456-64. PubMed ID: 27012865
[TBL] [Abstract][Full Text] [Related]
5. Minimal residual disease by either flow cytometry or cytogenetics prior to an allogeneic hematopoietic stem cell transplant is associated with poor outcome in acute myeloid leukemia.
Norkin M; Katragadda L; Zou F; Xiong S; Chang M; Dai Y; Hsu JW; Moreb JS; Leather H; Murthy HS; Farhadfar N; Li Y; Hromas R; Brown RA; Cogle CR; Wingard JR
Blood Cancer J; 2017 Nov; 7(12):634. PubMed ID: 29176662
[TBL] [Abstract][Full Text] [Related]
6. Hematopoietic cell transplantation for adults with acute myeloid leukemia with minimal residual disease.
Appelbaum FR
Best Pract Res Clin Haematol; 2015; 28(2-3):133-40. PubMed ID: 26590770
[TBL] [Abstract][Full Text] [Related]
7. The impact of pre-transplant minimal residual disease on outcome of intensified myeloablative cord blood transplant for acute myeloid leukemia in first or second complete remission.
Zheng C; Zhu X; Tang B; Zhang L; Geng L; Liu H; Sun Z
Leuk Lymphoma; 2016; 57(6):1398-405. PubMed ID: 26690538
[TBL] [Abstract][Full Text] [Related]
8. Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission.
Walter RB; Buckley SA; Pagel JM; Wood BL; Storer BE; Sandmaier BM; Fang M; Gyurkocza B; Delaney C; Radich JP; Estey EH; Appelbaum FR
Blood; 2013 Sep; 122(10):1813-21. PubMed ID: 23847197
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of allogeneic transplantation in first or later minimal residual disease - negative remission following adult-inspired therapy for acute lymphoblastic leukemia.
Cassaday RD; Alan Potts D; Stevenson PA; Bar M; Georges GE; Shustov AR; Sorror ML; Wood BL; Delaney C; Doney KC; Storb RF; Sandmaier BM
Leuk Lymphoma; 2016 Sep; 57(9):2109-18. PubMed ID: 27002921
[TBL] [Abstract][Full Text] [Related]
10. Impact of pretransplant minimal residual disease after cord blood transplantation for childhood acute lymphoblastic leukemia in remission: an Eurocord, PDWP-EBMT analysis.
Ruggeri A; Michel G; Dalle JH; Caniglia M; Locatelli F; Campos A; de Heredia CD; Mohty M; Hurtado JM; Bierings M; Bittencourt H; Mauad M; Purtill D; Cunha R; Kabbara N; Gluckman E; Labopin M; Peters C; Rocha V
Leukemia; 2012 Dec; 26(12):2455-61. PubMed ID: 22555150
[TBL] [Abstract][Full Text] [Related]
11. Comparison of chimerism and minimal residual disease monitoring for relapse prediction after allogeneic stem cell transplantation for adult acute lymphoblastic leukemia.
Terwey TH; Hemmati PG; Nagy M; Pfeifer H; Gökbuget N; Brüggemann M; Le Duc TM; le Coutre P; Dörken B; Arnold R
Biol Blood Marrow Transplant; 2014 Oct; 20(10):1522-9. PubMed ID: 24907626
[TBL] [Abstract][Full Text] [Related]
12. Flow cytometry-based measurable residual disease (MRD) analysis identifies AML patients who may benefit from allogeneic hematopoietic stem cell transplantation.
Lucero J; Alhumaid M; Novitzky-Basso I; Capo-Chichi JM; Stockley T; Gupta V; Bankar A; Chan S; Schuh AC; Minden M; Mattsson J; Kumar R; Sibai H; Tierens A; Kim DDH
Ann Hematol; 2024 Apr; 103(4):1187-1196. PubMed ID: 38291275
[TBL] [Abstract][Full Text] [Related]
13. Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia.
Walter RB; Gooley TA; Wood BL; Milano F; Fang M; Sorror ML; Estey EH; Salter AI; Lansverk E; Chien JW; Gopal AK; Appelbaum FR; Pagel JM
J Clin Oncol; 2011 Mar; 29(9):1190-7. PubMed ID: 21282535
[TBL] [Abstract][Full Text] [Related]
14. Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT.
Pavlů J; Labopin M; Niittyvuopio R; Socié G; Yakoub-Agha I; Wu D; Remenyi P; Passweg J; Beelen DW; Aljurf M; Kröger N; Labussière-Wallet H; Perić Z; Giebel S; Nagler A; Mohty M
J Hematol Oncol; 2019 Oct; 12(1):108. PubMed ID: 31647022
[TBL] [Abstract][Full Text] [Related]
15. Minimal residual disease after allogeneic stem cell transplant: a comparison among multiparametric flow cytometry, Wilms tumor 1 expression and chimerism status (Complete chimerism versus Low Level Mixed Chimerism) in acute leukemia.
Rossi G; Carella AM; Minervini MM; Savino L; Fontana A; Pellegrini F; Greco MM; Merla E; Quarta G; Loseto G; Capalbo S; Palumbo G; Cascavilla N
Leuk Lymphoma; 2013 Dec; 54(12):2660-6. PubMed ID: 23547840
[TBL] [Abstract][Full Text] [Related]
16. Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation.
Walter RB; Gyurkocza B; Storer BE; Godwin CD; Pagel JM; Buckley SA; Sorror ML; Wood BL; Storb R; Appelbaum FR; Sandmaier BM
Leukemia; 2015 Jan; 29(1):137-44. PubMed ID: 24888275
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Outcomes for Pediatric Patients With Acute Myeloid Leukemia in Remission and Undergoing Allogeneic Hematopoietic Cell Transplantation With Myeloablative Conditioning Regimens Based on Either Intravenous Busulfan or Total Body Irradiation: A Report From the Japanese Society for Hematopoietic Cell Transplantation.
Ishida H; Kato M; Kudo K; Taga T; Tomizawa D; Miyamura T; Goto H; Inagaki J; Koh K; Terui K; Ogawa A; Kawano Y; Inoue M; Sawada A; Kato K; Atsuta Y; Yamashita T; Adachi S
Biol Blood Marrow Transplant; 2015 Dec; 21(12):2141-2147. PubMed ID: 26271192
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission?
Araki D; Wood BL; Othus M; Radich JP; Halpern AB; Zhou Y; Mielcarek M; Estey EH; Appelbaum FR; Walter RB
J Clin Oncol; 2016 Feb; 34(4):329-36. PubMed ID: 26668349
[TBL] [Abstract][Full Text] [Related]
19. Measurable residual disease status and outcome of transplant in acute myeloid leukemia in second complete remission: a study by the acute leukemia working party of the EBMT.
Gilleece MH; Shimoni A; Labopin M; Robinson S; Beelen D; Socié G; Unal A; Ganser A; Vitek A; Sengeloev H; Yakoub-Agha I; Tholouli E; Polge E; Mohty M; Nagler A
Blood Cancer J; 2021 May; 11(5):88. PubMed ID: 33980810
[TBL] [Abstract][Full Text] [Related]
20. Interferon-α: A Potentially Effective Treatment for Minimal Residual Disease in Acute Leukemia/Myelodysplastic Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation.
Mo XD; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1939-47. PubMed ID: 26116088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
